Endocrine Abstracts

Prospective non-comparable randomized clinical investigation of GH/IGH-1 control and tumor growth reduction in active acromegalic patients on Octreotide-LAR is presented. Fifty patients (pts) with newly diagnosed acromegaly (primary teratment, group 1; mean age 47.8±13.9 years old) and 39 pts after previous surgical and/or radiological treatment (secondary treatment, group 2; mean age 48.1±12.2 years old) were treated with Ocrteotide LAR 20–40 mg every 4 weeks, ...